Physician profile
Eric Svenson
NPI 1669526398
$4,602.57
in general payments reported to CMS, 2019-2025
58 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $63.21 · 2021: $96.89 · 2022: $410 · 2023: $708 · 2024: $1,256 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $412.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $329.80 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $299.98 | 2023-2024 | Monoferric, Cosela |
| Geron Corporation | $245.60 | 2025 | Rytelo |
| Janssen Biotech, INC. | $236.90 | 2022-2025 | Rybrevant, Carvykti |
| Incyte Corporation | $226.59 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $190.66 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $183.15 | 2023-2025 | Lynparza, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $164.37 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Genzyme Corporation | $141.39 | 2021-2025 | |
| Genentech USA, INC. | $117.94 | 2023-2025 | Columvi, Lunsumio, Polivy |
| Pharmaessentia USA Corporation | $109.09 | 2023-2025 | Besremi |
| Merck Sharp & Dohme LLC | $100.97 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Sumitomo Pharma America, INC. | $100.30 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $99.41 | 2023-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $94.45 | 2020-2025 | Opdivo |
| Genmab U.S., INC. | $82.98 | 2023-2025 | Tivdak, Epkinly |
| Abbvie INC. | $82.10 | 2025 | |
| Taiho Oncology, INC. | $80.11 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.37 | 2024-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Aveo Pharmaceuticals, INC. | $69.00 | 2022-2024 | |
| Eisai INC. | $66.11 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $62.72 | 2023-2025 | Onivyde, Tazverik |
| Alnylam Pharmaceuticals INC. | $56.08 | 2024-2025 | Givlaari |
| Myovant Sciences INC. | $53.48 | 2022 | |
| Exelixis INC. | $52.45 | 2022-2025 | Cabometyx |
| Tactile Systems Technology INC | $48.49 | 2019-2022 | |
| Coherus Oncology, INC. | $47.90 | 2023-2024 | |
| Gilead Sciences, INC. | $44.66 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $44.04 | 2025 | Ojjaara |
| Seagen INC. | $43.53 | 2022-2023 | Padcev |
| Astellas Pharma US INC | $42.21 | 2024-2025 | Padcev |
| Blueprint Medicines Corporation | $41.61 | 2021-2023 | Ayvakit |
| Sobi, INC | $39.32 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $33.97 | 2024-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $29.47 | 2022 | |
| Dendreon Pharmaceuticals LLC | $27.51 | 2025 | Provenge |
| Amgen INC. | $27.21 | 2019-2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $26.92 | 2021-2023 | Precisetumor |
| Adc Therapeutics America, INC. | $25.27 | 2025 | |
| Mirati Therapeutics, INC. | $24.21 | 2024 | Krazati |
| Agios Pharmaceuticals, INC. | $24.12 | 2024 | Pyrukynd |
| Lilly USA, LLC | $23.23 | 2022 | |
| Beone Medicines USA, INC. | $21.49 | 2025 | Tevimbra |
| Blue Earth Diagnostics | $20.96 | 2020 | |
| Karyopharm Therapeutics INC. | $19.87 | 2024 | Xpovio |
| Invivyd INC | $19.37 | 2025 | Pemgarda |
| Csl Behring | $19.16 | 2025 | Privigen |
| Caris Mpi, INC. | $19.06 | 2025 | Mi Cancer Seek |
| Progenics Pharmaceuticals, INC. | $18.75 | 2022 | |
| G1 Therapeutics, INC. | $18.26 | 2022 | |
| Beigene USA, INC. | $18.01 | 2024 | Brukinsa |
| Monteris Medical Corporation | $17.91 | 2023 | Neuroblate |
| Tempus Ai, INC | $17.75 | 2024 | |
| Varian Medical Systems, INC. | $17.62 | 2019 | |
| Kite Pharma, INC. | $17.11 | 2025 | Yescarta |
| Stemline Therapeutics INC. | $16.08 | 2024 | Orserdu |
| Foundation Medicine, INC. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Svenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.